Neurochem (NRMX) Continues to race for the bottom. On Monday, the company said its Alzheimer's disease treatment candidate, Alzhemed, failed a late-stage trial. The NRMX says it has 15 to ... Read Full Story »
Not all of these are low closes but these hit new 52-week lows if not......Candela (CLZR) keeps hitting the list....Carmike Cinema's (CKEC)...if movies hit $4 Billion and they can't make ... Read Full Story »
Shares in Neurochem (NRMX) are down 30% today to a 52-week low of $3.70. According to The Associated Press "its Alzheimer's disease treatment candidate failed in a late-stage clinical trial."NRMX ... Read Full Story »
Some new data is helping two small biotech stocks today at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. The latest figure showed 26.6 million people ... Read Full Story »
(ADLR) Adolor said a complete response to the POI ‘Approvable’ Letter now targeted for 3Q 2007.(ALXN) Alexion Pharm says studies show efficacy and safety of it's Soliris in broad population ... Read Full Story »
Stock Tickers: AZN, BCRX, EHTH, CTIC, HW, NRMX, SBUX, WFMI, DUKIt's no secret we had the makings of a crummy week, but the market managed to turn itself back around ... Read Full Story »